|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/18 | |
| C07K 16/30 | |||
| A61P 35/02 | |||
| C07K 14/725 | |||
| C07K 14/47 | |||
| A61K 39/00 |
| (11) | Number of the document | 3092252 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15701442.4 |
| Date of filing the European patent application | 2015-01-08 | |
| (97) | Date of publication of the European application | 2016-11-16 |
| (45) | Date of publication and mention of the grant of the patent | 2019-09-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/010620 |
| Date | 2015-01-08 |
| (87) | Number | WO 2015/105973 |
| Date | 2015-07-16 |
| (30) | Number | Date | Country code |
| 201461924967 P | 2014-01-08 | US |
| (72) |
WIESTNER, Adrian U., US
SKARZYNSKI, Martin W., US
LINDORFER, Margaret A., US
TAYLOR, Ronald P., US
RADER, Christoph, US
VIRE, Bérengčre, FR
|
| (73) |
The U.S.A. as represented by the Secretary, Department of Health and Human Services,
Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325 MSC 7660, Bethesda, MD 20892-7660,
US
University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group, 250 West Main Street, Suite 300, Charlottesville, VA 22902, US |
| (54) | ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3D AND USE THEREOF |
| ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3D AND USE THEREOF |